How many new drugs were detected in Europe over the last year? Is cannabis getting stronger? How many Europeans have ever used an illicit drug? What are the latest policy developments in the region?
2015 European Drug Report package, presenting the most recent overview of the drug situation in Europe
Watch a short video summarising the main findings from the 2015 European Drug Report
What are the main psychosocial interventions used in drug treatment and to whom are they provided?
Drug consumption rooms: an overview of evidence and provision in Europe
An overview of the main trafficking routes for opioids from Asia into Europe
The misuse of benzodiazepines among high-risk opioid users in Europe
Register now for the Lisbon Addictions 2015 conference — a major new event in the addictions calendar.
What are the trends and developments shaping the drug problem across Europe? Find out in the latest update on 4 June
European drugs summer school 2015: Illicit Drugs in Europe: Demand, Supply and Public Policies, 29 June–10 July 2015, Lisbon, Portugal
Launch of the European Drug Report 2015, 4 June 2015
58th Commission on Narcotic Drugs, 9–17 March 2015, Vienna
Meeting with President of the European Parliament, Martin Schulz, 7 January 2015, Brussels
EMCDDA scientific paper award, 25 November 2014, Lisbon
Note: photos will open in a new tab and are hosted on fickr.com.
EDR 2015 — Get the facts
Drug consumption rooms
Misuse of benzodiazepines
What is decriminalisation?
Note: videos will open in a new tab and are hosted on YouTube.com.
(25.06.2015) Europe’s cities offer a valuable observation window on new drug trends and some are developing drug strategies of their own, says new EMCDDA report. Read more »
(17.06.2015) EMCDDA Director Wolfgang Götz is at the European Parliament today presenting to the Committee for Civil Liberties, Justice and Home Affairs (LIBE) highlights from the European Drug Report 2015. Read more »
(04.06.2015) Changing dynamics in the heroin market, the latest implications of cannabis use and new features and dimensions of the stimulant and 'new drugs' scene, are among the issues highlighted in this year's European Drug Report. Read more »
(21.04.2015) Providing effective treatment for those with cannabis use disorders is likely to become a matter of growing importance in European drug policy. Read more »
(23.03.2015) The EMCDDA publishes today its first overview of the drug situation in the Western Balkans. The report describes a region facing a complex array of drug use problems and associated health and social consequences. Read more »
(09.03.2015) New psychoactive substances (NPS or ‘new drugs’) were detected in the EU last year at the rate of around two per week, according to an EMCDDA report issued today. Read more »
(27.02.2015) Today, the EMCDDA is hosting a Euro-DEN meeting and is promoting new guidelines on: ‘When to call the emergency services for unwell recreational drug users’. Read more »
(16.02.2015) Today ECDC and EMCDDA have released a joint rapid risk assessment following a recent increase in the number of cases in Norway and the United Kingdom. Read more »
Drug profiles are scientifically sound descriptions of drugs
A synthetic substance, normally seen as a white powder, amphetamine acts as a stimulant of the central nervous system. Read more »
Barbiturates are synthetic substances manufactured as pharmaceutical products. They act as depressants of the central nervous system. Read more »
Benzodiazepines were introduced into medicine in 1961 and are widely used to treat anxiety and insomnia. Read more »
Despite some claims to the contrary, piperazine and its derivatives are synthetic substances that do not occur naturally. Read more »
Cannabis is one of the most widely consumed drugs throughout the world, and has been used since historical times. Read more »
Cocaine is a natural product extracted from the leaves of Erythroxylon coca Lam (coca leaves). Read more »
Fentanyl is a narcotic analgesic with a potency at least 80 times that of morphine used in both human and veterinary medicine. Read more »
‘Hallucinogenic mushrooms’ is the name commonly given to psychoactive fungi, containing hallucinogenic compounds. Read more »
Heroin is a crude preparation of diamorphine. It is a semisynthetic product obtained by acetylation of morphine. Read more »
Khat comprises the leaves and fresh shoots of a flowering evergreen shrub cultivated in East Africa and the S.W. Arabian Peninsula. Read more »
Mitragyna speciosa Korth. is a 4 to 16 metre high tropical tree. In Thailand, the tree and leaf-preparations from it are called kratom. Read more »
Lysergide (LSD) is a semi-synthetic hallucinogen, and is one of the most potent drugs known. Read more »
MDMA is a synthetic substance commonly known as ecstasy, although th latter term now covers a wide range of other substances. Read more »
A synthetic substance. Normally seen as a white powder, it acts as a stimulant of the central nervous system. Read more »
The psychoactive plant Salvia divinorum is a rare member of the mint family. Read more »
Synthetic cannabinoids are functionally similar to THC, the active principle of cannabis. Read more »
Synthetic cathinones are related to the parent compound cathinone, one of the psychoactive principals in khat. Read more »
A number of synthetic derivatives of cocaine have been investigated as potential pharmaceutical agent. Read more »
Domestic products such as spray deodorants, glue, lighter refills and spray air fresheners can be used as drugs. Read more »
European Drug Report 2015: Trends and developments
How many new drugs were detected in Europe over the last year? Is cannabis getting stronger? How many Europeans have ever used an illicit drug? What are the latest drug policy developments in the region? These are just some of the questions explored in the European Drug Report: Trends and developments.
EU drug markets report: a strategic analysis
The EU drug markets report is the first comprehensive overview of illicit drug markets in the European Union. It covers issues such as production, consumer markets, trafficking, organised crime and policy responses, along with a review of the markets for heroin, cocaine, cannabis, amphetamine, methamphetamine, ecstasy and new psychoactive substances.
Drug use, impaired driving and traffic accidents
This literature review provides a comprehensive report on the relationship between drug use, impaired driving and traffic accidents. It describes methodological issues, presents the results of studies and findings, and explores the relationship between drug use, driving impairment and traffic accidents.
New psychoactive substances in 2014
This report ('EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA') presents the key activities performed by the EMCDDA and Europol in 2014, including details on all the relevant activities on the information exchange, risk assessment and control of new psychoactive substances.
ECDC and EMCDDA guidance. Prevention and control of infectious diseases among people who inject drugs
This joint guidance report explores good public health practices that can support effective policies to reduce infections. HIV, hepatitis B and hepatitis C are mainly spread through the sharing of needles, syringes and drug preparation equipment or unprotected sexual contacts.
A year in review: Highlights from the EMCDDA’s General Report of Activities 2014
The series ‘A year in review’ contains the essence of the EMCDDA's General Report of Activities. It is designed to provide interested audiences with a brief, four-page summary of the agency’s achievements for the year concerned with a focus on key topics.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>
The EMCDDA is located at:
Praça Europa 1, Cais do Sodré
Tel. (351) 211 21 02 00
More contact information >>
Page last updated: Monday, 08 June 2015